查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856492

介入性神经学器材市场（依产品类型、应用、技术和最终用户划分）－全球预测，2025-2032年

Interventional Neurology Devices Market by Product Type, Application, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，介入性神经病学设备市场规模将达到 44.8 亿美元，复合年增长率为 9.45%。

关键市场统计数据
基准年 2024 21.7亿美元
预计年份：2025年 23.8亿美元
预测年份 2032 44.8亿美元
复合年增长率 (%) 9.45%

权威介绍器械类别、临床应用和手术技术，并与现代诊疗路径和相关人员标准相符。

介入性神经病学器材处于快速临床创新和不断发展的医疗服务模式的交汇点，这既为临床医生、医院管理者和医疗技术开发人员带来了机会，也带来了挑战。本报告首先整理了主要器械类别及其临床应用和手术流程，并阐述了不同技术如何整合到脑血管疾病的治疗流程中。我们重点介绍了一系列器械，从栓塞剂和血流导引系统到先进的弹簧圈、支架和血栓切除平台，并解释瞭如何在手术团队和影像环境下优化这些器械的应用。

器械创新、日益成熟的临床证据以及医疗服务模式的重建如何重新定义神经血管疾病治疗的治疗方法和应用动态

介入性神经病学领域正经历着变革性的转变，这主要得益于技术进步、临床证据的日益成熟以及医疗服务模式的重塑。近年来，日益精密的血流导向平台，以及线圈配置和支架设计的不断改进，重新定义了复杂动脉瘤的治疗阈值，并拓展了血管内治疗的选择范围。同时，取栓器械（尤其是抽吸导管和血栓摘取支架）的改进，提升了急性缺血性脑中风的治疗标准，而手术流程的优化则体现在器械设计、导管相容性以及辅助系统的整合等方面。

近期关税变化和贸易政策转变对医疗器材供应链和医院采购行为的更广泛的营运、采购和购买影响

美国政策的转变和关税调整对介入性神经病学器械生态系统有重大影响，波及供应链经济、筹资策略和国际采购决策。某些医疗设备组件和原材料关税的提高将增加依赖跨境供应链的製造商的投入成本。这种压力将促使製造商更严格地审查供应商合同，加快供应商多元化策略，并重新评估库存管理实践，以降低贸易相关成本波动带来的风险。

将产品差异化、临床应用需求、技术赋能因素和最终用户优先事项与采用和商业化选择联繫起来的可操作的细分洞察

透过精细的细分视角，我们可以发现不同产品类型、临床应用、技术平台和终端使用者环境之间存在着显着的动态差异，这些差异共同塑造了医疗器材製造商和医疗保健系统的策略重点。栓塞剂正朝着液体、微球和颗粒状栓塞剂的方向发展，实现客製化的栓塞方案。血流导向装置正在演变为具有不同输送性和孔隙率的差异化平台，例如 Fred、Pipeline 和 Surpass 系列装置。神经血管弹簧圈正展现出材料主导的差异化趋势，其中生物活性弹簧圈和水凝胶增强弹簧圈与传统铂金弹簧圈相比，展现出不同的癒合反应；支架结构则分为球囊扩张型和自扩张式，以应对解剖结构和手术操作的差异。血栓切除装置在操作上分为抽吸导管系统和血栓摘取支架，每种方式都会影响手术流程和影像需求。

区域法律规范、临床基础设施成熟度和製造生态系统如何塑造全球主要市场不同的采用模式

区域动态对器材研发、监管策略和临床应用模式有显着影响，美洲、中东和非洲以及亚太地区的市场驱动因素各不相同。在美洲，强大的急性中风诊疗网络、先进的影像基础设施以及综合医疗体系中集中的采购能力加速了尖端血栓切除术和血流导向装置的普及应用，而供应链因素和医保报销环境则影响着采购週期和应用速度。该地区的临床研究网络和註册登记系统有助于快速产生循证医学证据，从而支持器械的迭代改进和指南的纳入。

策略性企业行动和竞争定位，优先考虑联合商业化，以推动整合平台、证据产生和持续的临床应用。

介入性神经病学领域的竞争力取决于对研发的持续投入、策略伙伴关係以及以临床实践为导向的项目，这些因素共同推动了产品差异化和平台倡议。领先企业投入巨资优化器械的可输送性、材料科学和平台互通性，同时积极开展有针对性的临床研究和真实世界证据项目，以证实其性能主张。与学术中心和神经血管註册机构的合作提供了至关重要的数据，有助于扩大适应症范围和核准指南批准，从而增强临床医生的信心并提升医院采购委员会的评级。

为製造商、医疗系统和临床领导者提供切实可行的优先建议，以协调证据、供应弹性和商业化，从而实现永续应用。

产业领导者应优先考虑一系列切实可行的倡议，使产品开发、商业性合作和营运韧性与不断变化的临床和政策现实保持一致。首先，应投资强大的临床证据项目，这些项目不仅要涵盖急性手术指标，还要包含长期结果、病患报告指标和卫生经济学分析，以便引起医院采购负责人和支付方决策者的共鸣。此外，还应利用可操作的註册数据和真实世界绩效报告来补充临床试验，从而加快指南的纳入和支付方的认可。

采用混合方法的研究框架，结合一手研究和二手研究，以确保得出稳健且可重复的结论。

本研究整合了多方面的证据，采用混合方法，以主要相关人员参与和严谨的二次分析为核心，建构了介入性神经病学器材领域的全貌。主要资讯来源包括对临床意见领袖、介入医师、医院采购主管和器械研发专家的结构化访谈，以获取关于手术趋势、器械性能预期和机构优先事项的第一手观点。此外，本研究也补充了手术团队的匿名调查数据，以检验不同医疗环境下器械选择和使用动态的模式。

对临床、营运和政策动态进行简明扼要的综合分析，重点在于阐述推动设备普及和维持临床影响的综合优先事项。

总而言之，介入性神经病学器材处于临床创新、供应链复杂性和不断变化的医疗服务模式的快速交汇点，这些因素共同塑造了製造商、医疗服务提供者和支付方的策略重点。从栓塞剂和弹簧圈材料到先进的血流导引平台和血栓切除系统，器械的研发历程表明，材料科学、器械工程和手术技术如何协同发展以改善患者预后。同时，贸易政策的动态和关税相关的压力凸显了具有韧性的筹资策略和灵活的商业性安排的重要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 机器人辅助介入神经放射学技术在精准设备导航的应用日益广泛
  • 整合人工智慧影像处理软体以改善即时中风介入效果
  • 开发生物可吸收神经血管支架以减少长期器械併发症
  • 远端血管通路手术中，小型、低轮廓微导管越来越偏好
  • 扩展远端神经介入平台，以实现远端卒中取栓术的指导
  • 针对复杂患者特定解剖结构的客製化3D列印神经血管植入激增
  • 新一代栓塞剂的进展，包括更高的可见性和更可控的释放特性
  • 增加表面改质特殊血流导向装置，旨在促进内皮化
  • 利用巨量资料分析预测患者对神经血管内治疗的反应
  • 设备製造商与影像处理软体公司之间的策略伙伴关係促进了整合解决方案的开发。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 介入性神经学器材市场（依产品类型划分）

  • 栓塞剂
    • 液态栓塞剂
    • 微球
    • 颗粒栓塞剂
  • 血流分流装置
    • FRED
    • 管道装置
    • 超越流线型
  • 神经血管线圈
    • 生物活性线圈
    • 水凝胶线圈
    • 铂金线圈
  • 神经血管支架
    • 球囊扩张型支架
    • 自动扩张型支架
  • 血栓除去装置
    • 吸管
    • 支架取栓器

9. 介入性神经学器材市场（依应用领域划分）

  • 动脉瘤
  • 动静脉畸形
  • 颈动脉狭窄
  • 缺血性中风
  • 血管痉挛

第十章 介入性神经学器材市场（依技术划分）

  • 导管导引线系统
    • 亲水涂层
    • 聚合物涂层
  • 机械血栓切除术
  • 微导管系统
    • 附导线式微导管
    • 快速交换微导管
  • 溶栓剂
    • TPA
    • 尿激酶

第十一章 介入性神经学器材市场（依最终用户划分）

  • 门诊手术中心
  • 诊断影像中心
  • 医院
  • 介入性神经学诊所

12. 各地区介入性神经学器材市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 介入性神经病学器材市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国介入性神经学器材市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Medtronic plc
    • Stryker Corporation
    • Johnson & Johnson
    • Boston Scientific Corporation
    • Terumo Corporation
    • Penumbra, Inc.
    • MicroPort Scientific Corporation
    • Balt Extrusion SAS
    • Acandis GmbH
    • Kaneka Corporation
Product Code: MRR-742BD517FEBA

The Interventional Neurology Devices Market is projected to grow by USD 4.48 billion at a CAGR of 9.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.17 billion
Estimated Year [2025] USD 2.38 billion
Forecast Year [2032] USD 4.48 billion
CAGR (%) 9.45%

An authoritative introduction that maps device categories, clinical applications, and procedural technologies to contemporary care pathways and stakeholder decision criteria

Interventional neurology devices are at the intersection of rapid clinical innovation and evolving care delivery pathways, creating both opportunity and complexity for clinicians, hospital administrators, and medical technology developers. This report initiates with a focused overview that situates core device categories alongside clinical applications and procedural workflows, framing how distinct technologies integrate into treatment algorithms for cerebrovascular disease. Emphasis is placed on the continuum of devices, from embolic agents and flow diversion systems to advanced coils, stents, and thrombectomy platforms, and how these instruments are optimized within procedural teams and imaging environments.

In parallel, the introduction outlines how device-specific innovations such as liquid embolics, microspheres, and particulate embolics have influenced therapeutic choices for aneurysm and arteriovenous malformation interventions, while flow diversion devices including high-profile platforms have altered the approach to complex aneurysm management. The narrative also recognizes the differential roles of neurovascular coils-ranging from bioactive and hydrogel variants to traditional platinum coils-and the technical distinctions between balloon-expandable and self-expanding stent designs. The thrombectomy armamentarium, including aspiration catheters and stent retrievers, is positioned within acute ischemic stroke pathways, underscoring the time-sensitive nature of device performance.

Finally, the introductory section sets expectations for the report's analytical scope by describing how device categories interact with application areas such as aneurysm, arteriovenous malformations, carotid stenosis, ischemic stroke, and vasospasm. It explains how advances in guidewire systems, microcatheter platforms, mechanical thrombectomy techniques, and thrombolytic agents underpin procedural success, and how end users across ambulatory surgical centers, diagnostic imaging centers, hospitals, and specialized neuro interventional clinics shape adoption dynamics. This framing prepares readers for detailed downstream analysis of regulatory, clinical, economic, and operational factors that drive strategic choices across the ecosystem.

How converging device innovation, clinical evidence maturation, and care-delivery reconfiguration are redefining therapeutic approaches and adoption dynamics across neurovascular practice

The interventional neurology landscape is undergoing transformative shifts driven by converging technological advancements, clinical evidence maturation, and reconfigured care delivery models. Over recent years, the increasing refinement of flow diversion platforms-alongside iterative improvements in coil composition and stent design-has redefined therapeutic thresholds for complex aneurysms and expanded endovascular options. Concurrent enhancements in thrombectomy devices, specifically aspiration catheters and stent retrievers, have elevated the standard of care in acute ischemic stroke, with procedural refinements reflected in device design, catheter compatibility, and ancillary system integration.

Technological progress is complemented by advances in supporting systems such as guidewire variants with hydrophilic or polymer coatings, refined microcatheter architectures including over-the-wire and rapid-exchange designs, and evolving thrombolytic agents like tPA and urokinase that influence adjunctive strategies. These innovations are reshaping procedural workflows and prompting multidisciplinary teams to reassess training, imaging protocols, and peri-procedural care. Meanwhile, adoption patterns are shifting as care migrates beyond traditional hospital interventional suites to ambulatory surgical centers and specialized neuro interventional clinics that prioritize throughput, patient experience, and cost optimization.

Regulatory landscapes and payer policies are adapting to new evidence and real-world data collection, catalyzing a stronger focus on value demonstration and longitudinal outcomes. At the same time, manufacturers are pursuing portfolio consolidation and modular platform strategies to provide end-to-end procedural solutions. Taken together, these forces are producing a dynamic environment in which clinical efficacy, device interoperability, and care-delivery economics jointly determine successful product adoption and long-term clinical integration.

Evaluating the broad operational, sourcing, and procurement consequences of recent tariff changes and trade policy shifts on device supply chains and hospital purchasing behaviors

Policy shifts and tariff adjustments in the United States have material implications for the interventional neurology device ecosystem, impacting supply chain economics, procurement strategies, and international sourcing decisions. Increased tariffs on certain medical device components and raw materials elevate input costs for manufacturers who depend on cross-border supply chains. This pressure translates into heightened scrutiny of supplier contracts, an acceleration of supplier diversification strategies, and a reassessment of inventory management practices to mitigate exposure to trade-related cost volatility.

Manufacturers and distributors respond by accelerating localization and nearshoring initiatives where feasible, expanding dual-sourcing arrangements, and renegotiating commercial terms to preserve margins while maintaining competitive pricing for hospitals and imaging centers. Hospitals and ambulatory surgical centers, mindful of constrained budgets, intensify procurement diligence and prioritize devices supported by robust clinical data and predictable lifecycle costs. As a result, there is increased emphasis on total cost of ownership analyses, long-term service agreements, and arrangements that bundle consumables with device platforms to achieve price stability.

Clinicians and hospital administrators also adjust procurement timelines and capital planning to accommodate lead-time variability and potential tariff-related cost adjustments. Regulatory and compliance teams must remain vigilant to ensure that device modifications or supplier changes do not inadvertently affect regulatory status or clinical labeling. Finally, payers and health systems may scrutinize unit pricing and reimbursement pathways more closely, driving manufacturers to emphasize outcomes-based evidence and align commercial models with performance metrics that resonate with value-driven stakeholders.

Actionable segmentation insights that connect product differentiation, clinical application demands, technology enablers, and end-user priorities to implementation and commercialization choices

A granular segmentation lens reveals distinct dynamics across product types, clinical applications, technology platforms, and end-user settings that collectively shape strategic priorities for device manufacturers and health systems. Within product categories, differential innovation trajectories are evident: embolic agents have diversified into liquid embolics, microspheres, and particulate options that enable tailored embolization profiles, while flow diversion devices have evolved into differentiated platforms such as Fred, Pipeline devices, and Surpass streamlines that vary in deliverability and porosity. Neurovascular coils demonstrate material-driven differentiation with bioactive and hydrogel-enhanced coils offering distinct healing responses compared with traditional platinum coils, and stent architectures split between balloon-expandable and self-expanding designs to accommodate anatomical and procedural variability. Thrombectomy devices divide operationally between aspiration catheter systems and stent retrievers, each influencing procedural workflow and imaging requirements.

Application-based segmentation highlights how device choice aligns tightly to clinical goals. Aneurysm treatment prioritizes device conformability and long-term vessel remodeling, arteriovenous malformation interventions require precise embolic control, carotid stenosis management balances hemodynamic restoration with embolic protection, ischemic stroke care is dominated by time-to-revascularization imperatives, and vasospasm therapies emphasize targeted delivery and vessel-sparing profiles. Technology segmentation underscores the role of ancillary systems in enabling successful procedures: guidewire systems with hydrophilic or polymer coatings affect maneuverability, mechanical thrombectomy techniques demand compatible catheter and stent designs, microcatheter system variations influence crossing strategies and device deployment options, and thrombolytic agents such as tPA and urokinase remain central to adjunctive pharmacologic protocols.

End-user segmentation illuminates the influence of care settings on device adoption and utilization patterns. Ambulatory surgical centers and neuro interventional clinics often prioritize devices that optimize turnover, reduce anesthesia requirements, and simplify inventory, while diagnostic imaging centers and hospitals focus on integrated solutions that support complex case mixes and robust post-procedural monitoring. Understanding these segmentation interdependencies enables more precise targeting of clinical evidence generation, training programs, and commercial engagement models that resonate with specific procedural contexts and budgetary constraints.

How regional regulatory frameworks, clinical infrastructure maturity, and manufacturing ecosystems are shaping differentiated adoption patterns across major global markets

Regional dynamics exert substantial influence on device development, regulatory strategy, and clinical adoption patterns, with distinct market drivers apparent across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, robust acute stroke networks, advanced imaging infrastructure, and concentrated purchasing power among integrated health systems accelerate uptake of cutting-edge thrombectomy systems and flow diversion devices, while supply chain considerations and reimbursement environments shape procurement cycles and adoption pacing. Clinical research networks and registries in this region facilitate rapid evidence generation that supports iterative device improvements and guideline incorporation.

Europe, the Middle East & Africa present heterogeneous regulatory environments and reimbursement systems that require modular market entry strategies. Regulatory convergence across certain European jurisdictions simplifies some aspects of approval, but country-level reimbursement pathways and hospital procurement practices necessitate tailored value demonstration and local evidence generation. In parts of the Middle East and Africa, infrastructure constraints and workforce training needs influence the pace of adoption, creating opportunities for solutions that emphasize simplified workflows and robust clinical support.

Asia-Pacific is characterized by diverse adoption profiles driven by demographic trends, rising investment in stroke care pathways, and substantial manufacturing capacity. Several markets within the region present strong device manufacturing ecosystems and opportunities for collaborative innovation, while others prioritize cost-effective solutions compatible with constrained budgets. Across the region, rapid expansion of diagnostic imaging capabilities and growing emphasis on interventional neuroradiology training programs are important enablers of broader device utilization. Recognizing these regional distinctions is essential for designing regulatory strategies, clinical studies, and commercial partnerships that align with local system priorities.

Strategic corporate behaviors and competitive positioning that prioritize integrated platforms, evidence generation, and collaborative commercialization to drive durable clinical adoption

Competitive dynamics in interventional neurology are defined by a combination of sustained investment in R&D, strategic partnerships, and focused clinical engagement programs that drive product differentiation and platform evolution. Leading firms invest heavily to optimize device deliverability, material science, and platform interoperability, while pursuing targeted clinical studies and real-world evidence initiatives to substantiate performance claims. Collaborations with academic centers and neurovascular registries provide pivotal data that inform label expansions and guideline recognition, reinforcing clinician confidence and hospital purchasing committees' assessments.

In addition to organic product development, companies are actively pursuing portfolio rationalization and selective acquisitions to fill technology gaps-particularly where ancillary systems such as guidewires, microcatheters, and aspiration platforms create integrated solution opportunities. Distribution strategies are evolving to include direct engagement with large health systems, partnerships with specialist distributors for regional reach, and the development of training and proctoring programs to accelerate adoption. Service offerings that combine device supply with digital procedural analytics, long-term follow-up tools, and education pathways are emerging as differentiators that enhance provider loyalty and facilitate broader clinical uptake.

Finally, firms that demonstrate agility in responding to supply chain pressures, regulatory changes, and reimbursement complexity gain competitive advantage. Those that invest in transparent outcomes reporting and payer-engaged value frameworks position themselves to navigate pricing pressures and procurement scrutiny more effectively, while simultaneously reinforcing clinical credibility through sustained engagement with key opinion leaders and multidisciplinary treatment teams.

Practical and prioritized recommendations for manufacturers, health systems, and clinical leaders to align evidence, supply resilience, and commercialization for sustainable adoption

Industry leaders should prioritize a set of actionable initiatives that align product development, commercial engagement, and operational resilience with evolving clinical and policy realities. First, invest in robust clinical evidence programs that move beyond acute procedural metrics to encompass longitudinal outcomes, patient-reported measures, and health economics analyses that resonate with hospital procurement and payer decision-makers. Complement clinical trials with pragmatic registry data and real-world performance reporting to accelerate guideline inclusion and payer recognition.

Second, strengthen supply chain resilience by diversifying suppliers, implementing dual-sourcing strategies for critical components, and evaluating selective nearshoring opportunities to mitigate tariff and trade volatility. Establish clear inventory governance and collaborative forecasting arrangements with major health system customers to reduce lead-time risk. Third, design commercialization models that offer modular value propositions tailored to specific end users: packaged clinical support and training for ambulatory surgical centers, integrated platform solutions for high-volume hospitals, and targeted outreach for diagnostic imaging centers that support multidisciplinary workflows.

Fourth, prioritize interoperability and ease of use by harmonizing device interfaces with common imaging and navigation systems, while investing in digital support tools that enhance procedural planning and post-procedural follow-up. Finally, cultivate payer engagement strategies that emphasize outcomes-based approaches and total cost of care benefits, enabling negotiations that reflect device value in clinical pathways and support sustainable adoption across diverse healthcare settings.

A mixed-methods research framework combining primary clinician and procurement insights with systematic secondary analysis to ensure robust, reproducible conclusions

This research synthesizes multiple evidence streams to construct a comprehensive view of the interventional neurology device environment, leveraging a mixed-methods approach centered on primary stakeholder engagement and rigorous secondary analysis. Primary inputs include structured interviews with clinical thought leaders, interventionalists, hospital procurement executives, and device development experts to capture firsthand perspectives on procedural trends, device performance expectations, and institutional priorities. These qualitative engagements are supplemented by anonymized survey data from procedural teams to validate patterns of device selection and usage dynamics across different care settings.

Secondary research incorporates systematic review of peer-reviewed clinical literature, procedural registries, regulatory filings, and publicly available health system procurement documentation to ensure findings are grounded in documented clinical outcomes and policy contexts. Supply chain mapping and component sourcing analysis are conducted through supplier interviews and customs data review to identify exposure points and mitigation strategies. Triangulation across information sources is used to reconcile inconsistencies and strengthen confidence in thematic conclusions. Where appropriate, sensitivity analyses and scenario planning exercises are employed to explore the operational implications of policy shifts and technology adoption pathways.

Ethical standards and data privacy considerations governed the study's primary research activities, ensuring that interview and survey participants provided consent and that data were anonymized prior to analysis. The methodology emphasizes transparency and reproducibility by documenting data sources, interview protocols, and analytical frameworks available within the technical appendix for purchaser review.

A concise synthesis of clinical, operational, and policy dynamics that underscores the integrated priorities for advancing device adoption and sustaining clinical impact

In conclusion, interventional neurology devices occupy a rapidly evolving nexus of clinical innovation, supply chain complexity, and shifting care-delivery models that together dictate strategic priorities for manufacturers, providers, and payers. The trajectory of device development-from embolic agents and coil materials to advanced flow diversion platforms and thrombectomy systems-illustrates how material science, device engineering, and procedural technique co-evolve to improve patient outcomes. At the same time, trade policy dynamics and tariff-related pressures underscore the importance of resilient sourcing strategies and flexible commercial arrangements.

Strategic success in this environment depends on integrating rigorous clinical evidence generation with pragmatic supply chain planning and tailored commercialization approaches that respect the heterogeneity of end-user settings. Regional nuances in regulatory regimes, infrastructure maturity, and manufacturing capacity require bespoke market-entry and clinical engagement plans. Ultimately, stakeholders that align product innovation with demonstrable outcomes, transparent value propositions, and operational reliability will be best positioned to support clinicians in delivering advanced neurovascular care while navigating economic and policy headwinds.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of robotic-assisted neurointerventions for precise device navigation
  • 5.2. Integration of AI-powered imaging software to enhance real-time stroke intervention outcomes
  • 5.3. Development of bioresorbable neurovascular scaffolds to reduce long-term device complications
  • 5.4. Growing preference for compact low-profile microcatheters in distal vessel access procedures
  • 5.5. Expansion of tele-neurointervention platforms enabling remote stroke thrombectomy guidance
  • 5.6. Surge in customized 3D-printed neurovascular implants for patient-specific anatomical complexity
  • 5.7. Advances in next-generation embolic agents with improved visibility and controlled release profiles
  • 5.8. Increase in specialized flow diverters with surface modifications for enhanced endothelialization
  • 5.9. Leveraging big data analytics to predict patient response to endovascular neurology treatments
  • 5.10. Strategic partnerships between device manufacturers and imaging software firms driving integrated solutions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Interventional Neurology Devices Market, by Product Type

  • 8.1. Embolic Agents
    • 8.1.1. Liquid Embolics
    • 8.1.2. Microspheres
    • 8.1.3. Particulate Embolics
  • 8.2. Flow Diversion Devices
    • 8.2.1. Fred
    • 8.2.2. Pipeline Devices
    • 8.2.3. Surpass Streamlines
  • 8.3. Neurovascular Coils
    • 8.3.1. Bioactive Coils
    • 8.3.2. Hydrogel Coils
    • 8.3.3. Platinum Coils
  • 8.4. Neurovascular Stents
    • 8.4.1. Balloon-Expandable Stents
    • 8.4.2. Self-Expanding Stents
  • 8.5. Thrombectomy Devices
    • 8.5.1. Aspiration Catheters
    • 8.5.2. Stent Retrievers

9. Interventional Neurology Devices Market, by Application

  • 9.1. Aneurysm
  • 9.2. Arteriovenous Malformations
  • 9.3. Carotid Stenosis
  • 9.4. Ischemic Stroke
  • 9.5. Vasospasm

10. Interventional Neurology Devices Market, by Technology

  • 10.1. Guidewire Systems
    • 10.1.1. Hydrophilic Coated
    • 10.1.2. Polymer Coated
  • 10.2. Mechanical Thrombectomy
  • 10.3. Microcatheter Systems
    • 10.3.1. Over The Wire Microcatheters
    • 10.3.2. Rapid Exchange Microcatheters
  • 10.4. Thrombolytic Agents
    • 10.4.1. Tpa
    • 10.4.2. Urokinase

11. Interventional Neurology Devices Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospital
  • 11.4. Neuro Interventional Clinics

12. Interventional Neurology Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Interventional Neurology Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Interventional Neurology Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Stryker Corporation
    • 15.3.3. Johnson & Johnson
    • 15.3.4. Boston Scientific Corporation
    • 15.3.5. Terumo Corporation
    • 15.3.6. Penumbra, Inc.
    • 15.3.7. MicroPort Scientific Corporation
    • 15.3.8. Balt Extrusion SAS
    • 15.3.9. Acandis GmbH
    • 15.3.10. Kaneka Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INTERVENTIONAL NEUROLOGY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INTERVENTIONAL NEUROLOGY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTERVENTIONAL NEUROLOGY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PIPELINE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SURPASS STREAMLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PLATINUM COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY CAROTID STENOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY VASOSPASM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY RAPID EXCHANGE MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TPA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY UROKINASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEURO INTERVENTIONAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY GUIDEWIRE SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY MICROCATHETER SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY THROMBOLYTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS INTERVENTIONAL NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD